Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models by Loudon, P. et al.
PHARMACODYNAMICS
Demonstration of an anti-hyperalgesic effect
of a novel pan-Trk inhibitor PF-06273340 in a
battery of human evoked pain models
Correspondence Dr Donal Gorman, Neuroscience and Pain Research Unit, Pfizer WRD, Cambridge, UK. Tel.: +44 13 0464 1231;
E-mail: donal.gorman@pfizer.com
Received 23 November 2016; Revised 30 August 2017; Accepted 23 September 2017
Peter Loudon1, Pieter Siebenga2, Donal Gorman1 , Katrina Gore1, Pinky Dua1, Guido van Amerongen2,
Justin L. Hay2, Geert Jan Groeneveld2 and Richard P. Butt1
1Neuroscience and Pain Research Unit, Pfizer WRD, Cambridge, UK and 2Centre for Human Drug Research, Zernikedreef 8,2333 CL Leiden,
the Netherlands
Keywords pain, pharmacodynamics, phase I (drug development)
AIM
Inhibitors of nerve growth factor (NGF) reduce pain in several chronic pain indications. NGF signals through tyrosine kinase
receptors of the tropomyosin-related kinase (Trk) family and the unrelated p75 receptor. PF-06273340 is a small molecule in-
hibitor of Trks A, B and C that reduces pain in nonclinical models, and the present study aimed to investigate the pharmacody-
namics of this first-in-class molecule in humans.
METHODS
A randomized, double-blind, single-dose, placebo- and active-controlled five-period crossover study was conducted in healthy
human subjects (NCT02260947). Subjects received five treatments: PF-06273340 50 mg, PF-06273340 400 mg, pregabalin
300 mg, ibuprofen 600 mg and placebo. The five primary endpoints were the pain detection threshold for the thermal pain tests
and the pain tolerance threshold for the cold pressor, electrical stair and pressure pain tests. The trial had predefined decision rules
based on 95% confidence that the PF-06273340 effect was better than that of placebo.
RESULTS
Twenty subjects entered the study, with 18 completing all five periods. The high dose of PF-06273340 met the decision rules on
the ultraviolet (UV) B skin thermal pain endpoint [least squares (LS) mean vs. placebo: 1.13, 95% confidence interval: 0.64–1.61],
but not on the other four primary endpoints. The low dose did not meet the decision criteria for any of the five primary endpoints.
Pregabalin (cold pressor and electrical stair tests) and ibuprofen (UVB thermal pain) showed significant analgesic effects on ex-
pected endpoints.
CONCLUSIONS
The study demonstrated, for the first time, the translation of nonclinical effects into man in an inflammatory pain analgesic
pharmacodynamic endpoint using a pan-Trk inhibitor.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Inhibitors of nerve growth factor (NGF) have been shown to reduce pain in several chronic pain indications.
• Inhibitors of Trks A, B and C demonstrate pain reductions in a preclinical setting.
WHAT THIS STUDY ADDS
• This was the first demonstration of analgesic efficacy in humans using a pan-Trk inhibitor.
• The study confirmed the usefulness of the human evoked pain models to profile novel pain therapeutics in early clinical
development.
Introduction
Nerve growth factor (NGF) is a key mediator of chronic
pain. Administration of NGF to animals or to human sub-
jects causes pain [1], and studies with anti-NGF scavenging
monoclonal antibodies such as tanezumab have demon-
strated efficacy in phase III trials in several chronic pain in-
dications [2, 3]. NGF is a member of the neurotrophin
family that signals through both tyrosine kinase receptors
of the tropomyosin-related kinase (Trk) family and the un-
related p75 receptor. The neurotrophins comprise NGF,
which signals preferentially through TrkA, brain-derived
neurotrophic factor (BDNF) and neurotrophin 4 (NT-4),
which signal through TrkB, and neurotrophin 3 (NT-3),
which signals through TrkC. The neurotrophins are
equipotent at the p75 receptor. NGF signalling through
TrkA is known to induce both acute and chronic regulation
of pain signalling, through phosphorylation-dependent
regulation of ion channels involved in pain transmission
and upregulation of pain-related genes, respectively [4].
BDNF was also found to be implicated in nonclinical pain
signalling and was found to be upregulated in clinical pain
states in human subjects [5].
PF-06273340 is a peripherally restricted small molecule
inhibitor of Trks A, B and C, the structural formula of
which has been published previously [6]. It is equipotent
at the three Trk receptors but is otherwise broadly selective.
PF-06273340 and other molecules in this class reverse
chronic pain in nonclinical models where there has been
some sensitization, such as ultraviolet (UV) B sensitization
to the skin [6] or carrageenan irritation of the joint [7].
To date, there are no data on whether these analgesic
effects of small molecule pan-Trk inhibitors translate to
human subjects.
In the current study, the analgesic effects of PF-06273340
were assessed using a battery of human evoked pain models.
These models have been shown to provide robust evidence
of analgesia in healthy human subjects using a number of
positive controls assessed against different pain stimuli and
endpoints [8, 9]. By assessing PF-06273340 using this meth-
odology, we intended to establish whether the nonclinical
data demonstrating efficacy in the UVB sensitization model
would translate to human subjects. The inclusion of other
pain models in the study provided a comparison with
nonsensitized pain states. Furthermore, this would be the
first demonstration of analgesic efficacy for this novel class
of compounds in a small, easy-to-recruit trial prior to
investing in larger patient studies.
Methods
Subjects and study design
The study was a double-blind, double-dummy, single-dose,
randomized, placebo-controlled, five-period crossover study
(NCT02260947). PF-06273340 was the drug under investiga-
tion, and ibuprofen and pregabalin were used as positive con-
trols. The study was conducted at a single site at the Centre
for Human Drug Research in Leiden, the Netherlands. It was
approved by the Medical Ethics Committee of Stichting
Beoordeling Ethiek Biomedisch Onderzoek (Assen, the
Netherlands), and was conducted in accordance with the
Dutch Act on Medical Research Involving Human Subjects
(WMO) and in compliance with all International Conference
on Harmonization Good Clinical Practice (ICH-GCP) guide-
lines and the Declaration of Helsinki. Each subject provided
written informed consent before any screening procedures
were performed.
Approximately 20 healthy male subjects, between 18
and 55 years of age, were to attend the clinic on seven sep-
arate occasions (screening, periods 1–5 and at follow-up) to
examine the effects of PF-06273340 on evoked pain end-
points. Periods 1–5 were spaced apart by at least 7 days,
which, based on the half-lives of the single doses of treat-
ments, would give sufficient time to allow for the washout
of pharmacokinetic (PK) and potential pharmacodynamic
(PD) effects.
Study drugs
The study included placebo, ibuprofen and pregabalin (posi-
tive controls) and two dose levels of PF-06273340. Subjects
were randomized to one of 10 sequences that consisted of
two Williams 5 × 5 designs that were balanced for first-order
carry-over. At each investigational period, subjects received
a total of four tablets and one capsule: two tablets of 200 mg
PF-06273340/placebo, one tablet of 50 mg PF-06273340/
placebo, one tablet of 600 mg ibuprofen/placebo and one
capsule of 300 mg pregabalin/placebo. The doses of PF-
06273340 selected were 50 mg and 400 mg, given as single
doses. These doses were justified based on safety margins
elucidated in toxicology studies and on clinical toleration
and safety data from phase I single and multiple ascending
dose studies (https://clinicaltrials.gov/ct2/results?term=PF-
06273340) in healthy young and elderly subjects. The top
dose of 400 mg PF-06273340 was close to the maximum dose
given previously to human subjects, whereas the lower dose
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of 50 mg PF-06372865 allowed examination of the bottom
end of the predicted pharmacologically active range.
Doses of 600 mg ibuprofen and 300 mg pregabalin had
been used as positive controls in previous human evoked
pain model studies [8, 9]. These doses had been found to be
well tolerated and within the labelled dose range for ibupro-
fen and pregabalin in the European Union (EU).
PK assessments
During all study periods, blood samples (3 ml) to provide a
minimum of 1.5 ml plasma for PK analysis of PF-06273340,
pregabalin and ibuprofen were collected at predose and at
0.5, 1, 2, 3, 4, 5, 6, 8 and 10 h after study drug administration.
Plasma samples were analysed for PF-06273340, pregabalin
and ibuprofen concentrations at WuXi AppTec (Shanghai,
P.R. China) using validated analytical assays. Plasma PF-
06273340 PK parameters [maximum observed plasma con-
centration (Cmax), area under the plasma concentration–time
curve from time 0 to the time of last quantifiable concentra-
tion (AUClast) and time to reach Cmax (Tmax)] were calculated
for each subject using noncompartmental analysis of plasma
concentration–time data. Plasma ibuprofen and plasma
pregabalin concentrations were listed and summarized de-
scriptively (results not shown).
PD assessments
Pain detection and tolerance thresholds were measured
using a battery of human pain models that assess a range
of modalities of pain using previously described methodol-
ogy [8, 9]. Briefly, the pain models included thermode,
electrical stimulation, mechanical pain and cold pressor,
which were all performed sequentially at predose (twice)
and at 0.5, 1, 2, 3, 4, 6, 8 and 10 h after study drug admin-
istration in each period. Thermal (heat) pain was deter-
mined on normal skin and on UVB-exposed skin. Pain
intensity was measured continuously during each test
using an electronic visual analogue scale (eVAS) ranging
from 0 (no pain) to 100 (most intense pain tolerable).
The pain detection threshold (PDT) and pain tolerance
threshold (PTT) were of primary interest (see Supplemen-
tary data for more details).
Ibuprofen and pregabalin were included as active con-
trols, based on previous studies [8, 9]; ibuprofen had shown
effects on the UVB heat PDT endpoint and pregabalin had
shown effects on the cold pressor PTT, pressure pain PTT,
electrical stair PTT (pre-cold pressor) and normal heat PDT
endpoints.
Statistical analysis
A mixed-effects model was fitted to each endpoint, using
data collected during the first 6 h post-treatment. Absolute
values were analysed for PDT endpoints and loge trans-
formed values for PTT endpoints as the latter had been
shown to have skewed distributions in previous studies
[8, 9]. The fixed effects included in the model were baseline,
period, time, treatment and treatment-by-time interaction,
with baseline as covariate. Subject was fitted as a random
effect. Baseline was included as two separate variables –
the average baseline for the subject, and the deviation of
each period baseline from the average baseline for each
subject [10]. The Kenward–Roger approximation was used
for estimating degrees of freedom for the model parameters.
The primary analysis included all subjects randomized into
the study.
The least squares (LS) means, together with 90% confi-
dence intervals (CIs), were obtained for each treatment, aver-
aged across time points that covered the peak exposure for
each treatment. Based on the known human PK, the average
across the first 4 h was obtained from the mixed-effects
model for PF-06273340 and ibuprofen, whereas the average
across the first 6 h was obtained for pregabalin. The averages
over both the first 4 h and 6 h were obtained for placebo.
Differences between treatments and placebo were therefore
made using the appropriate average (i.e. ibuprofen was
compared with the placebo 4 h average, whereas pregabalin
was compared with the placebo 6 h average). Differences to
placebo are presented as absolute differences for PDT
endpoints and ratios for PTT endpoints, together with corre-
sponding 90% CIs.
As a sensitivity analysis to the primary analysis, a
mixed-effects model was fitted for the maximum (over
4 h or 6 h post-treatment, where appropriate) change from
baseline for each primary endpoint. The fixed effects in-
cluded in the model were baseline, period and treatment.
Baseline was similarly included as two separate variables.
Subject was fitted as a random effect. Additional sensitivity
analyses were conducted that applied the primary analysis
models to only subjects who completed all five treatment
periods or applied the models to all subjects but included
all time points (i.e. up to and including the 10 h
measurement).
Sample size
Decision rules were prespecified to quantify what was re-
quired in the primary objective of the study. The criteria were
based on a Bayesian interpretation of the results, assuming a
non-informative prior. The criterion used for each endpoint
was having at least 95% confidence that the effect of either
dose of PF-06273340 was greater than that of placebo. This
is equivalent to a one-sided test for statistical significance
using an alpha of 0.05. No adjustment was made for multi-
plicity as this was an early-phase clinical study designed to
explore the PD of PF-06273340 and, as such, no stringent re-
quirement to control the type 1 error rate was required for in-
ternal decision making.
The sample size was based on the mean effect over the
first 4 h after dosing (i.e. average of 0.5, 1, 2, 3 and 4 h time
points) for the five primary endpoints: cold pressor PTT;
pressure pain PTT; electrical stair PTT; normal heat PDT;
and UVB heat PDT. The primary comparison was of either
dose of PF-06273340 against placebo. A conservative esti-
mate of within-subject standard deviation was derived from
two previous methodology studies [8, 9], yielding estimates
of 0.25, 0.21, 0.16, 1.79 and 1.63 for the cold pressor PTT,
pressure pain PTT, electrical stair PTT, normal heat PDT
and UVB heat PDT endpoints, respectively. A sample size
of 20 subjects was selected to ensure balance in the design,
and gave at least 80% power to detect differences of 0.20,
0.17, 0.13, 1.42 and 1.30 for the five primary endpoints
listed previously.
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Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide
to PHARMACOLOGY [11], and are permanently archived in
the Concise Guide to PHARMACOLOGY 2015/16 [12].
Results
Subject disposition
Of the 20 subjects who were randomized, 18 completed the
study (Figure 1). Two subjects discontinued from the study:
one owing to failure to meet inclusion/exclusion criteria
(electrocardiogram abnormalities), who did not proceed to
period 5 (missed the PF-06273340 50 mg dose); and the
other subject owing to no longer being willing to participate
in the study, having received only treatments assigned to
periods 1 and 3 (only treated with PF-06273340 50 mg and
ibuprofen 600 mg, respectively). All 20 subjects were male,
with a mean age (standard deviation) of 26.0 (6.9) years
and body mass index of 23.7 (2.5) kg m–2 (Table 1). Fifteen
subjects reported ethnicity as ‘white’, with the five
remaining as ‘other’. All 20 subjects were dosed with
ibuprofen 600 mg, and 19 subjects were dosed with placebo,
PF-06273340 50 mg, PF-06273340 400 mg or pregabalin
300 mg.
PD
A summary of the results for the primary analyses are pre-
sented in Table 2 and Figure 2. PF-06273340 400 mg met
the decision criteria for the UVB heat PDT endpoint, as
shown by a statistically significant increase over placebo of
1.13 units (90% CI 0.64, 1.61). There were no statistically sig-
nificant effects of PF-06273340 50 mg relative to placebo on
any of the five primary endpoints. Ibuprofen showed a statis-
tically significant effect on the UVB heat PDT endpoint com-
pared with placebo, with an increase of 1.39 units (90% CI
0.91, 1.87). Pregabalin 300 mg had statistically significant ef-
fects over placebo on the cold pressor PTT (effect vs. placebo =
1.22, 90% CI 1.11, 1.34) and the electrical stair PTT (effect vs.
placebo = 1.09, 90%CI 1.01, 1.19). The time course profiles of
the five treatments across the five primary endpoints are pre-
sented in Figure 3. Sensitivity analyses gave similar results
(data not shown).
Safety
Single doses of PF-06273340 400 mg or PF-06273340 50 mg
administered to healthy male subjects were generally safe
and well tolerated in the present study. There were no serious
adverse events or other clinically significant adverse events
reported.
The most frequently reported all causality treatment-
related adverse events were dizziness (16 subjects: four sub-
jects in the PF-06273340 400 mg group, two subjects each
in the PF-06273340 50mg and placebo groups, and eight sub-
jects in the pregabalin group), somnolence (13 subjects: two
subjects each in the PF-06273340 50 mg and ibuprofen
groups, one subjects each in the PF-06273340 400 mg and
placebo groups, and seven subjects in the pregabalin group)
and fatigue (11 subjects: two subjects each in the PF-
06273340 400 mg and pregabalin groups, three subjects each
in the PF-06273340 50 mg and ibuprofen groups, and one
Figure 1
Disposition of subjects
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subject in the placebo group). All treatment-related adverse
events were mild in severity, except in one subject in the PF-
06273340 50mg treatment group, who had upper abdominal
pain which was moderate in severity and considered by the
investigator to be treatment related.
PK
The median plasma PF-06273340 concentration–time profile
is presented in Figure 4 and PK parameters are summarized
descriptively in Table 3.
PF-06273340 was rapidly absorbed following oral admin-
istration, with a mean Tmax of 1 h for both treatments. Cmax
and AUClast appeared to increase proportionally, with doses
from 50 mg to 400 mg, and between-subject variability in
plasma PF-06273340 exposure based on the geometric per-
centage coefficient of variation for Cmax and AUClast ranged
from 42% to 57%.
Discussion
This was the first study to test a novel candidate analgesic
agent targeting the NGF pathway using a panel of human
Table 1
Summary of demographic and baseline characteristics
All subjects














Mean (SD) 77.1 (8.1)
Range 62.7–95.4
Body mass index (kg m–2):
Mean (SD) 23.7 (2.5)
Range 18.2–29.7
Height (cm):
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evoked pain models. Previous studies had demonstrated that
these models provided a reproducible method to assess the
effects of analgesic drugs on a battery of evoked pain assess-
ments in healthy human subjects, with consistent results
obtained from the ibuprofen and pregabalin positive controls
[8, 9]. The current study confirmed previous results showing a
significant effect of ibuprofen on the UVB heat PDT assess-
ment, and of pregabalin on the cold pressor test. Pregabalin
also demonstrated a modest effect in the electrical stair PTT
which achieved statistical significance; this agent had dem-
onstrated an effect at this endpoint in some but not all previ-
ous studies [8, 9]. Overall, the results for the positive controls
(ibuprofen and pregabalin) confirmed the validity of this
methodology for detecting reproducible analgesic signals in
healthy human subjects.
The 400mg dose of pan-Trk inhibitor PF-06273340 signif-
icantly reduced the hyperalgesia seen in the UVB heat PDT
assessment but did not have an effect on any other endpoint.
This is similar to the pattern seen with ibuprofen and is in
agreement with the expected biology of the mechanism
of action of this molecule. NGF is upregulated in experimen-
tal models of inflammation, including UVB sensitization
[13, 14], and anti-NGF monoclonal antibodies and Trk inhib-
itors (including PF-06273340) have shown efficacy in non-
clinical models of inflammatory pain, e.g. involving the use
of complete Freund’s adjuvant, carrageenan and UVB radia-
tion [6, 15]. NGF has direct and indirect actions in inflamma-
tory pain (reviewed by Mantyh et al. [15]). Administration of
NGF leads to binding at TrkA on immune cells (including
mast cells) and the subsequent release of inflammatory medi-
ators which contribute to the sensitization of nociceptors. In
addition, NGF binding to TrkA on sensory nerve fibres elicits
signalling cascades which result in the trafficking of
nociceptors to the cell surface and their sensitization by
phosphorylation. One of the receptors that contributes to
increased signalling in this manner is the heat-sensitive ion
Figure 2
Primary analysis results. The comparisons of PF-06273340 vs. placebo, and ibuprofen vs. placebo were made with LS means averaged over 4 h.
The comparison of pregabalin vs. placebo was made with LS means averaged over 6 h. The purple horizontal dashed line represents no effect
over placebo. PTT endpoints are presented on the fold-change to placebo scale, whereas PDT endpoints are presented on the absolute differ-
ence to placebo scale. CI, confidence interval; LS mean, least squares mean; PDT, pain detection threshold; PTT, pain tolerance threshold;
UVB, ultraviolet B
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channel transient receptor potential cation channel subfam-
ily V member 1 (TRPV1), which is likely to be an important
component of the UV-induced hyperalgesia in man [16];
inhibition of TRPV1 signalling may be one component of
PF-06273340 efficacy in this model. The indirect effects of
NGF involve the retrograde transport of NGF–TrkA com-
plexes to the nucleus, where the transcription of nociceptors
and peptides involved in pain signalling are upregulated.
In vitro data have shown that this transport is inhibited by
PF-06273340 (Bilsland, personal communication), and this
may also contribute to the effect on UVB seen in the present
study, although the longer timescale of this process implies
that it may be more important in chronic pain states.
Given the proven efficacy of anti-NGF monoclonal anti-
bodies in nonclinical species and in human clinical studies,
it is tempting to ascribe the efficacy of PF-06273340 to a
blockade of TrkA signalling. However, a role for BDNF
(which signals through TrkB) cannot be discounted as it
has been shown to play a role in hyperalgesia and pain in
some nonclinical systems, and has been implicated in some
human biology studies in visceral and neuropathic pain
states [5]. The effects of NT-3 signalling through TrkC, and
NT-4 signalling through TrkB are not as well defined [17]
but published data do not suggest a major role in
nociception. One conclusion that can be drawn from the ef-
fects of PF-06273340 is that blockade of signalling through
p75 (which is spared by PF-06273340 but not by anti-NGF
monoclonal antibodies) is not required for an analgesic
effect in man.
The effect size of the 400 mg dose of PF-06273340 vs. pla-
cebo on the UVB endpoint was similar to that of ibuprofen;
however, the lower (50mg) dose of PF-06273340 did not have
a significant effect. The median exposure of PF-06273340 at
the top dose achieved was ~ 30 × IC50 at Cmax and dropped
to ~9 × IC50 at the end of the assessment period (4 h), whereas
the lower dose achieved was ~ 4 × IC50 at Cmax and dropped to
~1 × IC50 at 4 h. The differential efficacy of these two doses
implies that, at least for this endpoint, an exposure that
achieves a multiple of IC50 throughout the assessment period
is required for an acute PD effect in inflammatory pain. This
Figure 3
Time course of treatment effects across the five primary endpoints. The purple horizontal dashed line represents no effect over placebo. PTT end-
points are presented on the fold-change to placebo scale, whereas PDT endpoints are presented on the absolute difference to placebo scale. CI,
confidence interval; LS mean, least squares mean; PDT, pain detection threshold; PTT, pain tolerance threshold; UVB, ultraviolet B
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conclusion is consistent with the prediction from a systems
pharmacology model of the NGF pathway [18] utilizing
PF-06273340 data. Further studies are needed to determine
how these PD effects in a healthy volunteer study relate to
the exposures needed in patients with a chronic pain
condition.
The current study demonstrated, for the first time, that a
pan-Trkmolecule can reduce hyperalgesia in human subjects.
The observed effect in the presensitized UVB assessment is
consistent with the observed efficacy of anti-NGF monoclo-
nal antibodies in chronic pain states with an inflammatory
component, such as osteoarthritis (OA). We did not see a
significant impact on the cold pressor or electrical stair tests,
where pregabalin was shown to be effective. This may
indicate that the pan-Trk mechanism will be less effective in
neuropathic pain states where pregabalin has proven effi-
cacy; however, there is uncertainty regarding the translation
of studies in healthy human subjects to those with chronic
pain conditions, and it should be noted that the anti-NGF
monoclonal antibodies previously showed efficacy in neuro-
pathic pain [19], albeit at higher doses and exposures than
in the inflammatory pain state of OA. Another uncertainty
is how to interpret the effect size seen with the top dose of
PF-06273340, which was similar to that observed with ibu-
profen.We regard the primary role of the human evoked pain
models as being an early demonstration of PD for novel mol-
ecules, and to provide some guidance as to which pain states
might be selected for future clinical studies. Optimism that
pan-Trk inhibitors may be more efficacious that nonsteroidal
anti-inflammatory drugs such as ibuprofen comes from the
data with tanezumab showing superior efficacy to naproxen
in OA [2]. Given that the methodology in the present study
was limited by the use of single doses in a healthy subject
population, the translation of effect sizes to long-term dosing
in chronic pain states is uncertain, and will need to take
account of physiological responses such as changes to
nocioceptors and signalling pathways brought about by
chronic stimulation [20].
A concern of the anti-NGF monoclonal antibodies is the
increased risk of rapidly progressing OA (RPOA), which for
tanezumab monotherapy ranges from 0 events per 1000
patient-years at a dose of 2.5 mg, to 11 events per 1000
patient-years at a dose of 10 mg [21]. Small molecule pan-
Trk inhibitors have the potential advantages of greater flexi-
bility in dosing, and that once dosing is stopped the drug will
be rapidly eliminated compared with the much slower clear-
ance of a humanized monoclonal antibody. Whether the risk
of RPOA is reduced by small molecule pan-Trk inhibitors is
unknown. Given the low frequency of RPOA in subjects
who received anti-NGF monoclonal antibodies, an assess-
ment of this risk must await larger clinical trials, unless a
Figure 4
Median plasma PF-06273340 concentration–time profiles
Table 3





50 mg 400 mg
N 19 19
AUClast (ng•h ml
–1) 483.5 (42) 3630 (43)
Cmax (ng ml
–1) 150.4 (57) 1396 (56)
Tmax (h) 1.08 (1.00–3.00) 1.00 (0.500–2.00)
AUClast, area under the plasma concentration–time curve from time
0 to the time of last quantifiable concentration; Cmax, maximum
observed plasma concentration; %CV, percentage coefficient of
variation; Tmax, time to reach Cmax
aGeometric mean (geometric %CV) for all except: median (range)
for Tmax.
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predictive nonclinical model of RPOA becomes available. To
date, we have seen no safety concerns for joint damage in
our phase I programme.
In summary, the current study confirms the usefulness of
the human evoked pain models to profile novel pain thera-
peutics in early clinical development. The pan-Trk inhibitor
PF-06273340 demonstrated a significant effect in the UVB
heat PDT assessment, providing good evidence of a transla-
tion of nonclinical effects into man. This human pain model
is easy to execute, as a result of the small sample size of
healthy subjects needed, and we believe that it provides a
powerful method for demonstrating an analgesic effect for
novel pain medications.
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